Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

713 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Germinal center reactions in tertiary lymphoid structures associate with neoantigen burden, humoral immunity and long-term survivorship in pancreatic cancer.
J Gunderson A, Rajamanickam V, Bui C, Bernard B, Pucilowska J, Ballesteros-Merino C, Schmidt M, McCarty K, Philips M, Piening B, Dubay C, Medler T, Newell P, Hansen P, Tran E, Tang E, Bifulco C, Crittenden M, Gough M, Young KH. J Gunderson A, et al. Among authors: bernard b. Oncoimmunology. 2021 Mar 17;10(1):1900635. doi: 10.1080/2162402X.2021.1900635. Oncoimmunology. 2021. PMID: 33796412 Free PMC article.
Neoadjuvant anti-OX40 (MEDI6469) therapy in patients with head and neck squamous cell carcinoma activates and expands antigen-specific tumor-infiltrating T cells.
Duhen R, Ballesteros-Merino C, Frye AK, Tran E, Rajamanickam V, Chang SC, Koguchi Y, Bifulco CB, Bernard B, Leidner RS, Curti BD, Fox BA, Urba WJ, Bell RB, Weinberg AD. Duhen R, et al. Among authors: bernard b. Nat Commun. 2021 Feb 16;12(1):1047. doi: 10.1038/s41467-021-21383-1. Nat Commun. 2021. PMID: 33594075 Free PMC article. Clinical Trial.
Changes in T-cell subsets and clonal repertoire during chemoimmunotherapy with pembrolizumab and paclitaxel or capecitabine for metastatic triple-negative breast cancer.
Chun B, Pucilowska J, Chang S, Kim I, Nikitin B, Koguchi Y, Redmond WL, Bernard B, Rajamanickam V, Polaske N, Fields PA, Conrad V, Schmidt M, Urba WJ, Conlin AK, McArthur HL, Page DB. Chun B, et al. Among authors: bernard b. J Immunother Cancer. 2022 Jan;10(1):e004033. doi: 10.1136/jitc-2021-004033. J Immunother Cancer. 2022. PMID: 35086949 Free PMC article. Clinical Trial.
Transcriptomic profiles of neoantigen-reactive T cells in human gastrointestinal cancers.
Zheng C, Fass JN, Shih YP, Gunderson AJ, Sanjuan Silva N, Huang H, Bernard BM, Rajamanickam V, Slagel J, Bifulco CB, Piening B, Newell PHA, Hansen PD, Tran E. Zheng C, et al. Among authors: bernard bm. Cancer Cell. 2022 Apr 11;40(4):410-423.e7. doi: 10.1016/j.ccell.2022.03.005. Cancer Cell. 2022. PMID: 35413272 Free article.
Enhancing clinical and immunological effects of anti-PD-1 with belapectin, a galectin-3 inhibitor.
Curti BD, Koguchi Y, Leidner RS, Rolig AS, Sturgill ER, Sun Z, Wu Y, Rajamanickam V, Bernard B, Hilgart-Martiszus I, Fountain CB, Morris G, Iwamoto N, Shimada T, Chang S, Traber PG, Zomer E, Horton JR, Shlevin H, Redmond WL. Curti BD, et al. Among authors: bernard b. J Immunother Cancer. 2021 Apr;9(4):e002371. doi: 10.1136/jitc-2021-002371. J Immunother Cancer. 2021. PMID: 33837055 Free PMC article. Clinical Trial.
713 results